One Antivenom for a Thousand Snakes

India's Indian Polyvalent Anti-Venom (IPAV) is manufactured by immunizing horses with venom pooled from four species — Indian cobra, Russell's viper, saw-scaled viper, and common krait — collected from a single geographic source in peninsular southern India. Because venom composition varies substantially across India's ecological and geographic range, the resulting product is clinically ineffective against bites from conspecific populations in the north, east, and northeast of the country. Peer-reviewed studies show IPAV is completely ineffective against the monocled cobra in Arunachal Pradesh, fails to neutralize common krait venom from northern India, and shows insufficient efficacy in western Rajasthan. India records approximately 58,000 snakebite deaths annually — the highest national toll in the world — yet the mismatch between antivenom coverage and actual bite epidemiology has persisted for decades.

Snakebite was designated a Neglected Tropical Disease by the WHO in 2017, and India accounts for roughly half of global annual snakebite mortality. The burden is concentrated among agricultural laborers, tribal communities, and populations in eastern and northeastern states — groups with the least access to tertiary care and the longest transport times to facilities that stock antivenom. Children bitten in northeastern India may receive IPAV that neutralizes none of the relevant venom while clinicians administer escalating doses believing underdosing is the problem, accelerating serum sickness without improving survival. The combination of geographic inequity in sourcing and geographic inequity in exposure creates a compound injustice that is invisible in aggregate mortality statistics.

Manufacturers have had little regulatory or commercial incentive to reformulate, since IPAV's efficacy is tested in vitro against the immunizing venoms rather than against regionally representative panels. The Central Drugs Standard Control Organisation (CDSCO) approval standards have not required geographic venom representativeness. ICMR established the Centre of Excellence on Snakebite (CCoE) which has conducted regional venom collection and mapping, and India's National Action Plan for Snakebite Envenomation (NAPSE 2024) explicitly acknowledges regional venom variation and proposes regional venom collection centers. However, no regionalized antivenom product exists in production, and the capital cost of establishing multi-site immunization programs and running parallel clinical validation is beyond any single manufacturer's near-term planning horizon under current pricing constraints. Academic venom profiling papers have accumulated since 2010 but have not been systematically compiled into a mandatory regulatory dossier.

Mandating that CDSCO antivenom lot release testing include a geographically representative venom panel — covering at least five ecological zones — would create immediate regulatory pull for manufacturers to reformulate or produce regional variants. A publicly funded, ICMR-managed national venom biobank with GPS-referenced collection metadata would provide the assay substrate without requiring each manufacturer to build its own collection network. Pooling the NAPSE 2024 regional venom center proposal with a pre-competitive manufacturing consortium could reduce per-manufacturer capital risk while accelerating time to clinical trial.

A team with biology and data skills could audit all published Indian regional venom studies and produce the first integrated geographic mismatch map showing which species-region combinations lack IPAV coverage — a synthesis not yet formally compiled. A policy design team could compare regulatory venom representativeness requirements across Australia, Brazil, and the US and draft a model Indian standard amendment. A manufacturing process team could assess the cost delta between single-source and four-zone immunization programs using existing horse immunization facility data.